索拉非尼对肝癌术后早期肝功能及凝血功能影响的临床研究

目的 研究索拉非尼对肝癌术后早期肝功能及凝血功能的影响.方法 经病理确诊为肝癌,术后接受索拉非尼治疗者,共30例,分析不同剂量下、服药前及服药后1个月、3个月时肝功能及凝血功能的变化.结果 不同剂量对血清AST、ALT、TBIL、IBIL、ALB浓度及PT的影响均无统计学意义（P＞0.05）；服药前及服药后1个月时血清AST、ALT、TBIL、IBIL及ALB浓度变化无统计学意义（P＞0.05）,而血清PT变化有统计学意义（P＜0.05）.服药前及服药后3个月时血清TBIL、IBIL及ALB浓度变化无统计学意义（P＞0.05）,而血清AST、ALT浓度及PT变化有统计学意义（P＜0.05）.结论 索拉非尼可引起肝癌术后患者早期转氨酶升高,对早期凝血功能有抑制作用,且均与剂量无关.

Impacts of sorafenib on early liver function and blood coagulation in patients undergoing hepatectomy

Objective To investigate the impacts of sorafenib on liver function and blood coagulation in patients undergoing hepatectomy.Methods 30 patients with pathologically confirmed liver cancer received sorafenib at different doses.Liver function and blood coagulation were detected in all the patients before treatment and one and three months after treatment.Results There were no statistical significances among sorafenib at different doses in levels of AST,ALT,TBIL,IBIL,ALB,and PT （P〉0.05）.Concentrations of ALT,AST,TBIL,IBIL,and ALB did not change statistically one month after treatment as compared with the baseline values （P〉0.05） while PT changed significantly （P〈0.05）.There were no statistical significances in concentrations of TBIL,IBIL and ALB 3 month after treatment as compared with the baselines,but levels of ALT,AST,and PT differed significantly （P〈0.05）.Conclusions Sorafenib can induce an early elevation in levels of transaminases in patients undergoing hepatectomy,which plays a role in the inhibition of blood coagulation in a dose-independent fashion.